OncoMatch/Clinical Trials/NCT06246968
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Is NCT06246968 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Pembrolizumab and Cryoablation for metastatic breast cancer.
Treatment: Pembrolizumab · Cryoablation — Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Confirmed histologic diagnosis of metastatic TNBC
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06246968 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify